Washington, D.C. 20549

Form 6-K


For the month of November 2017

Commission File Number: 333-219066

Clementia Pharmaceuticals Inc.
(Translation of registrant's name into English)

4150 St Catherine Street West, Suite 550
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. 

On November 13, 2017, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated November 13, 2017


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Clementia Pharmaceuticals Inc.    
Date: November 13, 2017     /s/ MICHAEL SINGER    
  Michael Singer
  Chief Financial Officer


Clementia Reports Third Quarter 2017 Financial Results and Business Highlights

Initial Public Offering Completed, Raising $128.2 Million in Net Proceeds

U.S. FDA Grants Breakthrough Therapy Designation to Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP)

On Track to Begin Pivotal MOVE Study in FOP Later this Year

MONTREAL, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company, today reported financial results for the quarter ended September 30, 2017 and provided an update on recent corporate and clinical developments.

“With the successful completion of our initial public offering we have the necessary resources to initiate our Phase III MOVE Trial evaluating palovarotene for FOP this quarter, as well as our Phase II/III MO-Ped Trial evaluating palovarotene for multiple osteochondromas (MO) in early 2018,” commented Clarissa Desjardins, chief executive officer of Clementia. “The MOVE Trial is the first-ever Phase III clinical trial for the treatment of patients with FOP, and we look forward to working closely with patients and investigators around the world to complete this study while also advancing our clinical programs for MO and dry eye disease in 2018.”

Recent Corporate Highlights

Upcoming Milestones

Third Quarter 2017 Financial Results (all amounts are presented in U.S. dollars.)

About Clementia Pharmaceuticals Inc.
Clementia is a clinical-stage biopharmaceutical company committed to delivering treatments to people who have none. The Company is developing its lead candidate palovarotene, a novel RARγ agonist, to treat fibrodysplasia ossificans progressiva (FOP), multiple osteochondromas (MO, also known as hereditary multiple exostoses), and other diseases. For more information, please visit www.clementiapharma.com.

Cautionary Note Regarding Forward-Looking Statements
This press release may include “forward-looking statements” within the meaning of the applicable securities laws. Each forward-looking statement contained in this press release is subject to known and unknown risks and uncertainties and other unknown factors that could cause actual results to differ materially from historical results and those expressed or implied by such statement. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “will,” or “plans” to be uncertain and forward-looking. Applicable risks and uncertainties include, among others, our ability to generate revenue and become profitable; the risks related to our heavy reliance on palovarotene, our only current product candidate; the risks associated with the development of palovarotene and any future product candidate, including the demonstration of efficacy and safety; our heavy dependence on licensed intellectual property, including our ability to source and maintain licenses from third-party owners; as well as the risks identified under the heading “Risk Factors” in our Prospectus on Form 424(b) filed with the Securities and Exchange Commission (“SEC”), as well as the other information we file with the SEC or on SEDAR.  We caution investors not to rely on the forward-looking statements contained in this press release when making an investment decision in our securities.  You are encouraged to read our filings with the SEC or on SEDAR, available at www.sec.gov or www.sedar.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this press release, and we undertake no obligation to update or revise any of these statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor/Media Contact:
Joseph Walewicz
Clementia Pharmaceuticals Inc.

Chelcie Lister
THRUST Investor Relations

Clementia Pharmaceuticals Inc.
Interim Condensed Consolidated Statements of Financial Position (unaudited)
As at
(in US dollars)
 September 30,

  December 31,
Current assets   
Cash $37,238,196 $9,434,495 
Short-term investments  40,000,000  30,000,000 
Interest receivable  260,082  307,579 
Sales tax and other receivables  175,840  90,966 
Investment tax credits receivable  350,747  139,223 
Prepaid expenses  4,459,864  652,158 
Total current assets  82,484,729  40,624,421 
Non-current assets   
Long-term investments  75,000,000  - 
Property and equipment  35,330  38,163 
Intangible assets  1,763,866  894,584 
Total non-current assets  76,799,196  932,747 
Total assets $159,283,925 $41,557,168 
Current liabilities   
Accounts payable and accrued liabilities $6,371,234 $4,521,537 
Income taxes payable  119,925  2,176 
Total current liabilities  6,491,159  4,523,713 
Non-current liabilities   
Preferred shares  -  67,880,952 
Embedded derivatives  -  117,824,611 
Total non-current liabilities  -  185,705,563 
Total liabilities $6,491,159  190,229,276 
Common shares  230,659,692  272,391 
Contributed surplus  1,956,515  498,471 
Deficit  (79,823,441) (149,442,970
Total equity  152,792,766  (148,672,108)
Total equity and liabilities $159,283,925 $41,557,168 

Clementia Pharmaceuticals Inc.
Interim Condensed Consolidated Statements of Net Loss and Comprehensive Loss (unaudited)
   Three-month periods ended
September 30,

 Nine-month periods ended
September 30,

(in US dollars)   2017  2016  2017  2016 
Research and development expenses  $7,073,872 $4,490,048 $16,813,902 $11,544,330 
Investment tax credits   (91,484) (31,154) (211,524) (106,099)
    6,982,388  4,458,894  16,602,378  11,438,231 
General and administrative expenses   2,816,980  696,403  6,878,786  2,564,282 
Interest income   (316,081) (94,626) (503,915) (310,062)
Financial expenses (income)   29,415,957  (3,477,195) 80,440,739  (4,671,170)
Net loss before income taxes   38,899,244  1,583,476  103,417,988  9,021,281 
Income tax expense   106,310  43,569  248,338  116,527 
Net loss and comprehensive loss($39,005,554)($1,627,045)($103,666,326)($9,137,808)
Basic and diluted loss per share ($1.83)($0.69)($11.81)($3.89)
Weighted average number of outstanding basic and diluted shares  21,317,604  2,351,347  8,778,602  2,351,347 

Clementia Pharmaceuticals Inc.
Interim Condensed Consolidated Statements of Cash Flows (unaudited)
  Three-month periods ended
September 30,

 Nine-month periods ended
September 30,

(in US dollars)  2017  2016  2017  2016 
Operating activities     
Net loss ($39,005,554)($1,627,045)($103,666,326)($9,137,808)
Adjusting items     
Interest income recognized in net loss  (316,081) (94,626) (503,915) (310,062)
Depreciation of property and equipment  6,063  8,418  19,855  26,137 
Amortization of intangible assets  48,673  34,570  130,718  102,957 
Transaction costs recognized in net loss  -  -  35,175  - 
Embedded derivative loss recognized in net loss  29,007,078  (4,430,279) 77,902,663  (7,346,146)
Accretion of preferred shares  393,425  942,203  2,479,161  2,786,261 
Share-based compensation  795,806  42,982  1,478,082  142,985 
Net foreign exchange gain  (32,634) 14,313  (48,026) (116,753)
Income tax expense recognized in net loss 106,310  43,569  248,338  116,527 
Income taxes paid  (42,500) (32,939) (130,589) (38,219)
Net changes in working capital     
Sales tax and other receivables  (49,860) (46,264) (74,884) (30,505)
Investment tax credits receivable  (91,484) 136,408  (211,524) 271,802 
Deferred financing costs  275,784  -  -  - 
Prepaid expenses  (3,727,642) (267,872) (3,807,706) (706,665)
Accounts payable and accrued liabilities  457,938  1,714,117  1,835,789  721,711 
Net operating cash flows  (12,714,678) (3,562,445) (24,313,189) (13,517,778)
Investing activities     
Interest income received  184,040  52,624  551,412  83,077 
Acquisition of short and long-term investments  (109,000,000) -  (134,000,000) (40,000,000)
Maturity of short-term investments  19,000,000  10,000,000  49,000,000  10,000,000 
Acquisition of property and equipment  (4,194) (1,138) (17,022) (20,613)
Acquisition of intellectual property  -  -  (1,000,000) - 
Net investing cash flows
  (89,820,154) 10,051,486  (85,465,610) (29,937,536)
Financing activities     
Issuance of common shares  -  -  31,588  - 
Issuance of common shares upon public offering  137,865,000  -  137,865,000  - 
Share issuance costs  (10,236,593) -  (10,236,593) - 
Issuance of preferred shares  -  -  10,000,080  - 
Issue costs of preferred shares  -  -  (129,520) - 
Net financing cash flows  127,628,407  -  137,530,555  - 
Net increase (decrease) in cash
  25,633,575  6,489,041  27,751,756  (43,455,314)
Cash at beginning of period  11,584,221  8,298,313  9,434,495  58,106,885 
Effect of exchange rate fluctuations on cash held 20,400  (15,355) 51,945  120,428 
Cash at end of period $37,238,196 $14,771,999 $37,238,196 $14,771,999